Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia.
about
Novel agents and biomarkers for acute lymphoid leukemiaCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaA sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest ChinaFavorable outcome of allogeneic hematopoietic stem cell transplantation followed by post-transplant treatment with imatinib in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation.Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus.The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies.Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party oPreventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention.Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia.Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.Presence of CD34(+)CD38(-)CD58(-) leukemia-propagating cells at diagnosis identifies patients at high risk of relapse with Ph chromosome-positive ALL after allo-hematopoietic SCT.Tyrosine Kinase Inhibitor for Treatment of Adult Allogeneic Hematopoietic Stem Cell Transplantation Candidate with Philadelphia-Positive Acute Lymphoblastic Leukemia.Umbilical cord blood transplantation and unmanipulated haploidentical hematopoietic SCT for pediatric hematologic malignances.Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation.Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation.Prophylactic post-transplant dasatinib administration in a pediatric patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.Taming of the shrew--overcoming extramedullary blast crisis in the era of the new tyrosine kinase inhibitors.Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.
P2860
Q26829775-24EDD639-3433-469F-9843-CE5A2207063EQ27025242-BE37A1D9-54BF-4787-9A72-62681DA6898FQ33822032-861DE882-8FE2-4685-AAC4-428F13E2BA2EQ35888941-7ADC03F6-ABB7-4869-834B-C4195C88F362Q36128159-A9702D28-1F51-40E5-BC9F-64030C53E35DQ37426542-3481CDC9-120E-49F9-B023-F8CFCAC17364Q37552083-F0F1818B-45FA-43A8-AA67-4E356B2CC3C3Q38207017-1F8A47D8-272D-4417-B153-B688AC42A38CQ38674733-9EEED4BE-F34A-4F7F-A0E7-E8447817A8C5Q38698520-8B7B2D01-5798-49DC-B38C-AEDE9D20438FQ38759431-BF37C569-37C6-49A0-8E59-E371A86EEDBFQ38866851-E9E0AB14-F944-43C6-BFA2-901AE3498698Q39329093-E8006536-6A89-49F5-B8BD-2B9E8CFFECEEQ40675515-208BD65F-5C94-41DD-A7DE-AA10C8915BC9Q41571058-B7DD1845-F64E-48EF-AC9D-DFEC46F21CF0Q41715958-FB4C614E-9EFE-429D-B765-EF00CCEE01BCQ42325811-6BDD89DD-9739-4AE8-A185-680B64F50703Q43481632-C2E6009D-C0E4-4F92-9447-193761850264Q45351795-9175C569-ABF7-4FC2-8F5C-9ECB4A8AA59BQ46341511-3F098EC3-41AA-416E-9439-585B8AD3F5F9Q50863410-41E1ABD6-42D3-47B1-B712-9B4781F1A5C2Q54424684-B6099AF8-FDF8-4BB7-84D2-F4234C3259DAQ54440145-589E22AA-FDCF-430B-A5D7-B2F36C7CA47CQ55263277-7C97FBA1-6ADC-4B68-8DF6-2B7C3BE6780B
P2860
Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Administration of imatinib aft ...... acute lymphobla stic leukemia.
@ast
Administration of imatinib aft ...... acute lymphobla stic leukemia.
@en
type
label
Administration of imatinib aft ...... acute lymphobla stic leukemia.
@ast
Administration of imatinib aft ...... acute lymphobla stic leukemia.
@en
prefLabel
Administration of imatinib aft ...... acute lymphobla stic leukemia.
@ast
Administration of imatinib aft ...... acute lymphobla stic leukemia.
@en
P2093
P2860
P356
P1476
Administration of imatinib aft ...... acute lymphobla stic leukemia
@en
P2093
Dai-hong Liu
Kai-yan Liu
Lan-ping Xu
Xiang-yu Zhao
Xiao-hui Zhang
Ya-zhen Qin
Yan-rong Liu
P2860
P2888
P356
10.1186/1756-8722-5-29
P577
2012-06-08T00:00:00Z
P5875
P6179
1042061405